Equities research analysts forecast that Acorda Therapeutics, Inc. (NASDAQ:ACOR) will post $0.94 earnings per share for the current quarter, Zacks reports. Eight analysts have provided estimates for Acorda Therapeutics’ earnings. The highest EPS estimate is $1.10 and the lowest is $0.75. Acorda Therapeutics reported earnings per share of $0.05 in the same quarter last year, which would suggest a positive year over year growth rate of 1,780%. The firm is scheduled to issue its next earnings report on Tuesday, February 13th.

On average, analysts expect that Acorda Therapeutics will report full year earnings of $1.61 per share for the current fiscal year, with EPS estimates ranging from $1.48 to $1.75. For the next year, analysts forecast that the firm will report earnings of $0.40 per share, with EPS estimates ranging from ($1.19) to $2.97. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Acorda Therapeutics.

Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.69 by ($0.26). The company had revenue of $141.07 million during the quarter, compared to analyst estimates of $150.64 million. Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. Acorda Therapeutics’s revenue was up 4.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.04) earnings per share.

Several equities analysts have weighed in on the company. Oppenheimer Holdings, Inc. assumed coverage on Acorda Therapeutics in a report on Thursday, November 9th. They issued a “market perform” rating and a $27.00 price objective for the company. CIBC assumed coverage on Acorda Therapeutics in a report on Thursday, November 9th. They issued a “market perform” rating for the company. Zacks Investment Research cut Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, November 6th. HC Wainwright assumed coverage on Acorda Therapeutics in a report on Wednesday, November 8th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and issued a $20.00 price objective on shares of Acorda Therapeutics in a report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $25.60.

TRADEMARK VIOLATION WARNING: “Acorda Therapeutics, Inc. (ACOR) Expected to Announce Earnings of $0.94 Per Share” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/14/acorda-therapeutics-inc-acor-expected-to-announce-earnings-of-0-94-per-share.html.

Shares of Acorda Therapeutics (NASDAQ:ACOR) traded down $0.25 during midday trading on Tuesday, reaching $27.70. The company’s stock had a trading volume of 552,600 shares, compared to its average volume of 894,958. The company has a quick ratio of 2.40, a current ratio of 2.77 and a debt-to-equity ratio of 0.49. Acorda Therapeutics has a 52-week low of $13.60 and a 52-week high of $33.00.

In other Acorda Therapeutics news, major shareholder Scopia Capital Management Lp purchased 766,201 shares of the firm’s stock in a transaction dated Tuesday, August 29th. The shares were bought at an average price of $19.23 per share, for a total transaction of $14,734,045.23. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 7.90% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Louisiana State Employees Retirement System grew its position in Acorda Therapeutics by 0.5% during the 2nd quarter. Louisiana State Employees Retirement System now owns 19,000 shares of the biopharmaceutical company’s stock worth $374,000 after acquiring an additional 100 shares during the last quarter. Arizona State Retirement System grew its position in Acorda Therapeutics by 0.4% during the 2nd quarter. Arizona State Retirement System now owns 24,305 shares of the biopharmaceutical company’s stock worth $479,000 after acquiring an additional 100 shares during the last quarter. Aperio Group LLC grew its position in Acorda Therapeutics by 2.7% during the 2nd quarter. Aperio Group LLC now owns 12,972 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 343 shares during the last quarter. Municipal Employees Retirement System of Michigan grew its position in Acorda Therapeutics by 3.9% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 10,960 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 410 shares during the last quarter. Finally, Texas Permanent School Fund grew its position in Acorda Therapeutics by 1.4% during the 2nd quarter. Texas Permanent School Fund now owns 34,066 shares of the biopharmaceutical company’s stock worth $671,000 after acquiring an additional 466 shares during the last quarter.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related stocks with our FREE daily email newsletter.